Avidity Biosciences, Inc. (RNA)
$6.46
+0.08 (+1.25%)
Rating:
Recommendation:
-
| Symbol | RNA |
|---|---|
| Price | $6.46 |
| Beta | -0.091 |
| Volume Avg. | 0.78M |
| Market Cap | 478.661M |
| Shares () | - |
| 52 Week Range | 6.2-25.74 |
| 1y Target Est | - |
| DCF Unlevered | RNA DCF -> | |
|---|---|---|
| DCF Levered | RNA LDCF -> | |
| ROE | -35.54% | Strong Sell |
| ROA | -30.16% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 1.70% | Neutral |
| P/E | -2.09 | Sell |
| P/B | 0.82 | Buy |
Latest RNA news
About
Download (Excel)Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.